Whether your goal is to develop a pipeline through commercial launch or partner as early as possible, submitting a Clinical Trial Application (CTA) is a critical early milestone for every biotech company. With big pharma and Venture Capital firms competing for the most promising compounds, startups are expected to demonstrate a clear blueprint for their CTA approach, and need to get ready. During this session you can tap into Dutch expertise to help you potentially refine your strategy.
Johnson & Johnson Innovation – JLABS invites you to an in-depth look into CMC strategies and clinical trial design as part of the large molecule CTA. This webinar takes places online on 24 November 2020 from 15:00 – 17:00 hours CET. Register here: http://jlabs.buzz/colorizeblueprint
Source: JLABS